Context: In this study, controlled ciprofloxacin (CIPRO) nanostrustructured lipid carriers of Precirol((R)) ATO 5/Transcutol((R)) HP (batch A) and tallow fat/Transcutol((R)) HP (batch B) was carreid out. Objective: The aim was to improve solubility and bioavailability of CIPRO.Objective: Study of controlled ciprofloxacin (CIPRO) nanostructured lipid carriers of Precirol((R)) ATO 5/Transcutol((R)) HP (batch A) and tallow fat/Transcutol((R)) HP (batch B).Methods: CIPRO concentrations C1-5 (0.0, 0.2, 0.5, 0.8, and 1.0% w/w) as AC(1-5) and BC1-5 were prepared by hot homogenisation and characterised by zetasizer, differential scanning calorimetry, Fourier transform infra-red spectroscopy, in vitro drug release and growth inhibitory zone diameter (IZD) on agar-seeded Bacillus subtilis.Results: AC(5) achieved polydispersed particles of approximate to 605nm, 92% encapsulation efficiency (EE) and -28mV similar to BC5 (approximate to 789nm, 91% EE, and -31mV). Crystallinity indices (AC(5) and BC5) were low at 3 and 5%, respectively. CIPRO release in AC(5) was approximate to 98% in SGF (pH 1.2) and BC5 similarly approximate to 98% in SIF (pH 6.8).Conclusions: AC(5) had superior growth inhibition of B. subtilis at lower concentration (1.2 mu g/mL) than BC5 and CIPRO controls; hence could serve as possible sustained delivery system of CIPRO.